Direxion Daily S&P Biotech Bull 3X ETF (LABU)
| Assets | $552.40M |
| Expense Ratio | 0.96% |
| PE Ratio | n/a |
| Shares Out | 2.52M |
| Dividend (ttm) | $1.23 |
| Dividend Yield | 0.70% |
| Ex-Dividend Date | Dec 23, 2025 |
| Payout Ratio | n/a |
| 1-Year Return | +225.74% |
| Volume | 502,370 |
| Open | 183.13 |
| Previous Close | 185.30 |
| Day's Range | 176.94 - 190.82 |
| 52-Week Low | 44.69 |
| 52-Week High | 212.45 |
| Beta | 2.59 |
| Holdings | 170 |
| Inception Date | May 28, 2015 |
About LABU
Fund Home PageThe Direxion Daily S&P Biotech Bull 3X ETF (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is issued by Direxion.
Top 10 Holdings
48.86% of assets| Name | Symbol | Weight |
|---|---|---|
| Dreyfus Govt Cash Man Ins | n/a | 19.38% |
| Goldman Finl Sq Trsry Inst 506 | n/a | 8.19% |
| S&P Biotechnology Select Industry Index Swap | n/a | 5.71% |
| S&P Biotechnology Select Industry Index Swap | n/a | 3.83% |
| S&P Biotechnology Select Industry Index Swap | n/a | 2.93% |
| S&P Biotechnology Select Industry Index Swap | n/a | 2.87% |
| Goldman Sachs Fin Gov 465 Institut | n/a | 1.71% |
| S&P Biotechnology Select Industry Index Swap | n/a | 1.63% |
| S&P Biotechnology Select Industry Index Swap | n/a | 1.31% |
| Apellis Pharmaceuticals, Inc. | APLS | 1.30% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2025 | $0.90971 | Dec 31, 2025 |
| Sep 23, 2025 | $0.10273 | Sep 30, 2025 |
| Jun 24, 2025 | $0.21897 | Jul 1, 2025 |
| Mar 25, 2025 | $0.10714 | Apr 1, 2025 |
| Jun 25, 2024 | $0.15021 | Jul 2, 2024 |
| Mar 19, 2024 | $0.16064 | Mar 26, 2024 |
News
Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs
Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push towa...
A Biotech ETF For Aggressive, Risk-Tolerant Investors
The biotechnology sector has been on fire thanks to news from Biogen Inc. (NASDAQ: BIIB). The FDA approved its controverisal drug that can treat Alzheimer's Disease.
Heating Up: Three Leveraged ETFs For Summer Earnings
As the broad market knocks on the door of all-time highs in the midst of a still-raging public health crisis, traders have had to simultaneously ride the bullish wave (in most sectors) while also mode...
With Biotech Scorching, Traders Show LABU Love
The coronavirus pandemic is fueling gains for biotechnology exchange traded funds this year and the leverage members of this group are participating in the fun.
3 Leveraged Healthcare ETFs Soaring This Month
The new coronavirus from China has claimed more than 800 lives and there are now more than 37,000 documented cases of the respiratory illness worldwide, making it more deadly than the 2003 SARS epidem...
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.